Matthew Carpenter, Ph.D.

I am a senior investigator serving as Hollings Cancer Center's Associate Director of Behavioral and Population Science. As one of several inaugural faculty recruits within the Cancer Prevention and Control Program, I am proud to have contributed to the growth and success of the CPC program since its inception (in 2006). I am a clinical psychologist with strong research expertise in behavioral science, particularly addictive behaviors and smoking cessation.  This latter experience includes several clinical trials for both cessation ad cessation induction, including several large-scale nationwide studies that evaluated behavioral interventions to prompt cessation: 1) smoking reduction (N=616); 2) several trials of NRT (Ns=849, 157, 1245) or varenicline (N=651) sampling; and 3) alternative tobacco products (N=1236). We recently led what we believe is the largest (N=638) naturalistic clinical trial of e-cigarettes in the US. These pragmatic trials test the real-world impact of providing medication or product sampling to smokers, determining if and how they promote engagement and success in the quitting process. Each of these studies builds upon our continued goal to advance the methods for remote, decentralized clinical trials, leveraged in part by my role within the MUSC South Carolina Clinical and Translational Science Award (CTSA) as a campus leader on virtual clinical trials. I regularly take pre-and postdoctoral trainees and am proud to have been awarded the Peggy Schachte Mentoring Award at MUSC.